Overview

* ADC Therapeutics ( ADCT ) Q3 net income and income from operations beat analyst expectations

* Net product revenues for Q3 2025 declined due to lower sales volume

* Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet

Outlook

* ADC Therapeutics ( ADCT ) expects LOTIS-7 data by end of 2025

* Company anticipates LOTIS-5 topline results in 1H 2026

* Recent financing extends cash runway into 2028

Result Drivers

* PIPE FINANCING - Completed $60 mln PIPE financing to support ZYNLONTA expansion and strengthen balance sheet

* REVENUE DECLINE - Lower sales volume led to a decline in Q3 net product revenues despite higher prices

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$40.97 -$43 mln

Income mln (5

Analysts

)

Q3 Beat -$30.97 -$34.60

Income mln mln (5

from Analysts

Operatio )

ns

Q3 Basic -$0.30

EPS

Q3 -$47.40

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for ADC Therapeutics SA ( ADCT ) is $7.50, about 46.1% above its November 7 closing price of $4.04

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)